Skip to main content

Affymetrix Plans Notes Offering of $105M to Help Pay for eBioscience Acquisition

NEW YORK (GenomeWeb News) – Affymetrix intends to offer $105 million in convertible senior notes due 2019, it announced after the close of the market on Monday.

The proceeds from the offering, which was made pursuant to a $200 million shelf registration filed by the Santa Clara, Calif.-based microarray firm late last month, will be used to pay for part of its proposed buy of eBioscience for $315 million. Affy has a commitment letter from General Electric Capital and Silicon Valley Bank in the principal amount of $100 million for the acquisition, which is expected to close in the second quarter.

Citigroup and Morgan Stanley are joint book-running managers for the offering. Affy said it anticipates granting the two investment banks the option to purchase up to $10 million aggregate principal amount of additional notes to cover over-allotments, if any.

The eBioscience acquisition had been expected to close by the end of 2011, when it was originally announced in November with a purchase price of $330 million. A lawsuit delayed the deal, though, and Affy had to restructure the purchase.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.